These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 30085274)

  • 1. Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma.
    Cho HJ; Zhao J; Jung SW; Ladewig E; Kong DS; Suh YL; Lee Y; Kim D; Ahn SH; Bordyuh M; Kang HJ; Sa JK; Seo YJ; Kim ST; Lim DH; Dho YS; Lee JI; Seol HJ; Choi JW; Park WY; Park CK; Rabadan R; Nam DH
    Neuro Oncol; 2019 Jan; 21(1):47-58. PubMed ID: 30085274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma.
    Park AK; Kim P; Ballester LY; Esquenazi Y; Zhao Z
    Neuro Oncol; 2019 Jan; 21(1):59-70. PubMed ID: 30053126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and pathogenesis of cerebellar glioblastoma.
    Takahashi Y; Makino K; Nakamura H; Hide T; Yano S; Kamada H; Kuratsu J
    Mol Med Rep; 2014 Nov; 10(5):2383-8. PubMed ID: 25199771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
    Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
    Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
    Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
    J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative multi-omics characterization reveals sex differences in glioblastoma.
    Jang B; Yoon D; Lee JY; Kim J; Hong J; Koo H; Sa JK
    Biol Sex Differ; 2024 Mar; 15(1):23. PubMed ID: 38491408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GBM-associated mutations and altered protein expression are more common in young patients.
    Ferguson SD; Xiu J; Weathers SP; Zhou S; Kesari S; Weiss SE; Verhaak RG; Hohl RJ; Barger GR; Reddy SK; Heimberger AB
    Oncotarget; 2016 Oct; 7(43):69466-69478. PubMed ID: 27579614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments.
    Shen Y; Grisdale CJ; Islam SA; Bose P; Lever J; Zhao EY; Grinshtein N; Ma Y; Mungall AJ; Moore RA; Lun X; Senger DL; Robbins SM; Wang AY; MacIsaac JL; Kobor MS; Luchman HA; Weiss S; Chan JA; Blough MD; Kaplan DR; Cairncross JG; Marra MA; Jones SJM
    Proc Natl Acad Sci U S A; 2019 Sep; 116(38):19098-19108. PubMed ID: 31471491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.
    Eskilsson E; Røsland GV; Solecki G; Wang Q; Harter PN; Graziani G; Verhaak RGW; Winkler F; Bjerkvig R; Miletic H
    Neuro Oncol; 2018 May; 20(6):743-752. PubMed ID: 29040782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A heat shock protein 90 inhibitor reduces oncoprotein expression and induces cell death in heterogeneous glioblastoma cells with EGFR, PDGFRA, CDK4, and NF1 aberrations.
    Ho KT; Chen PF; Chuang JY; Gean PW; Hsueh YS
    Life Sci; 2022 Jan; 288():120176. PubMed ID: 34848192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
    Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characteristics and clinical features of multifocal glioblastoma.
    Dono A; Wang E; Lopez-Rivera V; Ramesh AV; Tandon N; Ballester LY; Esquenazi Y
    J Neurooncol; 2020 Jun; 148(2):389-397. PubMed ID: 32440969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular profiling of long-term IDH-wildtype glioblastoma survivors.
    Burgenske DM; Yang J; Decker PA; Kollmeyer TM; Kosel ML; Mladek AC; Caron AA; Vaubel RA; Gupta SK; Kitange GJ; Sicotte H; Youland RS; Remonde D; Voss JS; Fritcher EGB; Kolsky KL; Ida CM; Meyer FB; Lachance DH; Parney IJ; Kipp BR; Giannini C; Sulman EP; Jenkins RB; Eckel-Passow JE; Sarkaria JN
    Neuro Oncol; 2019 Nov; 21(11):1458-1469. PubMed ID: 31346613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma.
    Cheng W; Zhang C; Ren X; Jiang Y; Han S; Liu Y; Cai J; Li M; Wang K; Liu Y; Hu H; Li Q; Yang P; Bao Z; Wu A
    J Neurosurg; 2017 Jan; 126(1):249-259. PubMed ID: 26967788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and prognostic significance of TCTN1 in human glioblastoma.
    Meng D; Chen Y; Zhao Y; Wang J; Yun D; Yang S; Chen J; Chen H; Lu D
    J Transl Med; 2014 Oct; 12():288. PubMed ID: 25304031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative proteogenomic characterization of glioblastoma.
    Asif S; Fatima R; Krc R; Bennett J; Raza S
    CNS Oncol; 2019 Jun; 8(2):CNS37. PubMed ID: 31290679
    [No Abstract]   [Full Text] [Related]  

  • 17. An integrative characterization of recurrent molecular aberrations in glioblastoma genomes.
    Sintupisut N; Liu PL; Yeang CH
    Nucleic Acids Res; 2013 Oct; 41(19):8803-21. PubMed ID: 23907387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor gamma as a theragnostic target for mesenchymal-type glioblastoma patients.
    Hua TNM; Oh J; Kim S; Antonio JM; Vo VTA; Om J; Choi JW; Kim JY; Jung CW; Park MJ; Jeong Y
    Exp Mol Med; 2020 Apr; 52(4):629-642. PubMed ID: 32280134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated genomic analysis of survival outliers in glioblastoma.
    Peng S; Dhruv H; Armstrong B; Salhia B; Legendre C; Kiefer J; Parks J; Virk S; Sloan AE; Ostrom QT; Barnholtz-Sloan JS; Tran NL; Berens ME
    Neuro Oncol; 2017 Jun; 19(6):833-844. PubMed ID: 27932423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebellar glioblastoma: a clinical series with contemporary molecular analysis.
    Hong B; Banan R; Christians A; Nakamura M; Lalk M; Lehmann U; Hartmann C; Krauss JK
    Acta Neurochir (Wien); 2018 Nov; 160(11):2237-2248. PubMed ID: 30203362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.